

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033

Last Approval: 4/10/2024
Next Review Due By: April 2025



DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment, and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

OVERVIEW

Sacroiliac Joint (SIJ) pain is a condition in which pain is caused by the joint connecting the sacrum and the pelvis (Sun et al. 2018). The SIJ, the largest axial joint in humans, connects the sacrum to the ilium in the spine and functions more as a stabilizing than a moving joint. Numerous major ligaments and muscle groups contribute to the joint's stability. Pain may occur in this highly innervated joint or in the muscles and ligaments that surround it. The SIJ has been identified as a primary source of chronic low back pain (LBP). SIJ pain is defined as pain caused by an injury, disease, or surgery to the SIJ and/or its supporting ligamentous tissues (Wieczorek et al. 2021).

Sacroiliac (SI) injections are intraarticular injections performed for both diagnostic and therapeutic purposes. Diagnostic injections are performed to confirm the location of pain originating in the SIJ region. The current “gold standard” for SIJ diagnosis and treatment is to administer injections of a corticosteroid or anesthetic drug under fluoroscopic guidance to achieve pain relief (Thawrani et al. 2019). Fluoroscopy guidance is used for accurate needle placement during the procedure. The needle is inserted into the SIJ region, and contrast media is injected for arthrogram viewing to confirm proper needle placement.

Radiofrequency Ablation (RFA) is a treatment for SIJ pain that utilizes radiofrequency current to generate heat and destroy SIJ sensory nerves. In patients with refractory SIJ pain, the goal of this therapy is to disrupt pain signal transmission from the SIJ nerves to the brain. RFA is also referred to as Radiofrequency (RF) neurolysis, RF neurotomy, RF coagulation, RF lesioning, and RF denervation (Lee et al. 2021). Alternatives to conventional (consistent, thermal) RFA include cooled radiofrequency ablation (CRFA) and pulsed radiofrequency ablation (PRFA). CRFA and PRFA are both percutaneous procedures that use radiofrequency energy. Typically, both procedures are performed on an outpatient basis and are guided by fluoroscopy.

Cooled Radiofrequency Ablation (CRFA) uses radiofrequency energy to heat tissue to the point of ablation, preventing pain signals from reaching the central nervous system (Lee et al. 2021; Wray et al. 2022). CRFA probes differ from standard RFA probes in that water circulated through the CRFA probe tip draws heat away from the tissue-tip interface. The continuous flow of water cools the multichannel electrode, preventing it from reaching high tissue temperatures, allowing a continuous flow of RF current to produce a larger ablation zone, or lesion, which is thought to improve the chances of successful interventional capture of the target nerve within the lesion zone. This has been proposed to help achieve better or equal results when compared to conventional radiofrequency.

Pulsed Radiofrequency Ablation (PRFA) has been introduced as a non-ablative alternative to RFA. Unlike traditional RFA and CRFA, the goal of PRFA is not to create a thermal lesion, and the precise mechanism by which PRFA relieves pain is unknown. PRFA provides radiofrequency current in short bursts instead of continuous current, allowing the tissue to cool between bursts. Tissue can cool between bursts results in significantly lower maximum temperatures compared to the continuous mode and reducing the risk of tissue damage to neighboring tissue. It does not destroy targeted nerves and surrounding tissue; therefore, requiring less precise electrode placement. Evidence suggests that the electrical fields produced during PRFA may disrupt the pain signal to the brain (Hayes¹ 2023). During PRFA, the energy signal is delivered in short (20-millisecond) high-voltage pulses every half second for 120 seconds, keeping the probe temperature between 39 and 42 degrees Celsius.

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033

Last Approval: 4/10/2024
Next Review Due By: April 2025



Regulatory Status

SIJ injection with corticosteroids and/or local anesthetics is a procedure and thus not regulated by the FDA. Any medical devices, drugs, biologics, or tests used as part of this procedure may be subject to FDA regulation.

RFA (e.g., CRFA, PRFA) for spinal pain is a procedure and is not regulated by the FDA. The FDA regulates RFA equipment, and various devices approved for use in RFA for neurosurgical operations are listed in the FDA 510(k) database that have been cleared as class II devices by the FDA. These devices are classified into two product codes: radiofrequency lesion generators (GXD) and radiofrequency lesion probes (GXI).

RELATED POLICIES

MCP-085: Radiofrequency Ablation (RFA) for Chronic Back Pain Associated with the Facet Joint

COVERAGE POLICY

- A. Radiofrequency ablation (RFA) (including water cooled RFA) and pulsed radiofrequency ablation (PRFA) is **considered experimental, investigational, or unproven** for the treatment of acute, subacute, or chronic sacroiliac injections (SIJ) pain and may NOT be authorized due to insufficient evidence in the peer-reviewed literature.
- B. Sacroiliac (SI) injections (local anesthetics with or without corticosteroids) with fluoroscopy* is **considered medically necessary** for chronic severely debilitating low back pain (LBP) in adults who are age 18 years or older as part of a comprehensive pain management treatment program when **ALL** the following criteria are met:
 1. Physical examination documentation reveals **ALL** the following clinical characteristics of SIJ disease:
 - a. Somatic or non-radicular low back pain and lower extremity pain (greater than 6 on scale 0-10) below the level of L5 vertebra a minimum of three (3) months
 - b. Intermittent or continuous pain causing functional disability
 2. Inadequate response to conservative therapy that includes **ALL** the following:
 - a. Physical therapy (PT) a minimum of four (4) weeks (3-4 times per week for a total of 12 sessions); or documentation of the basis for PT contraindication. If ANY of the following conditions exist, PT may be contraindicated:
 - Pain worsened with physical therapy
 - Physical therapy tried but was not able to be tolerated
 - b. Activity modification a minimum of six (6) weeks
 - c. Drug therapy (e.g., NSAIDS, muscle relaxants, corticosteroids, antidepressants, anticonvulsants, or opiates)

**Imaging guidance with fluoroscopy is required for SIJ injections to ensure proper needle placement (this is considered integral to the primary procedure and not separately reimbursable).*

Limitations and Exclusions

The following are considered **experimental, investigational, and unproven** based on insufficient evidence:

1. **Lateral nerve blocks and RFA (including water cooled RFA) and PRFA** for diagnosing or treating acute, subacute, or chronic SIJ pain procedures are considered experimental, investigational, or unproven and may NOT be authorized due to insufficient evidence in the peer-reviewed literature
2. Any indications other than those listed above

SI injections are considered **contraindications/exclusions** based on insufficient evidence:

Exclusions to receiving SI injections include:

1. Members that do not meet the outlined criteria listed above
2. Use of agents other than local anesthetic agents with or without corticosteroids

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033



Last Approval: 4/10/2024

Next Review Due By: April 2025

3. SIJ injections performed without imaging guidance
4. Requests for SI injections exceeding the limits outlined above
5. Treatment of patients with acute low back and acute pain syndromes

Contraindications to receiving SI injections include:

1. Allergy to the medication to be administered
2. Anticoagulation therapy
3. Bleeding disorder
4. Localized infection in the region to be injected
5. Systemic infection
6. Other comorbidities that could exacerbate the procedure/steroid use (e.g., diabetes, congestive heart failure, poorly controlled hypertension)
7. Pregnancy: Fluoroscopy use is contraindicated for members that are pregnant

QUANTITY LIMITATION

Initiation of Treatment and Injection Frequency following Criteria Approval:

1. In the diagnostic phase:
 - a. **TWO (2)** injections for diagnosis may be given no less than **ONE (1)** week apart, preferably **TWO (2)** weeks apart
 - b. If the member does not experience significant functional pain relief of 50% measured by a decrease in pain medications and increase in physical function for a minimum of **TWO (2)** months, no further injections should be given
2. In the therapeutic phase **ALL** the following criteria must be met:
 - a. The previous diagnostic or therapeutic injection provided symptom or significant functional pain relief of 50% measured by a decrease in pain medications and increase in physical function for a minimum of **TWO (2)** months before subsequent injections within the same region are authorized
 - b. The frequency should be **TWO (2)** months or longer between each injection in the same joint not to exceed a total of FOUR (4) injections in one region per year. The injections should only be repeated as necessary if the medical necessity criteria above are achieved
 - c. Injections at different joints can be given **TWO (2)** weeks apart but no sooner than one (1) week following an injection in a different region
 - d. A maximum of **FOUR (4)** injections total per rolling calendar year may be given for local anesthetic and corticosteroid injections
 - e. A member must be experiencing a return of pain or deterioration in function to receive a therapeutic injection
 - A rolling calendar year is 12 months after the event, beginning and ending in the same month the initial event took place; (e.g., first diagnostic injection is given in June 2022, the rolling calendar year would end in June 2023)
 - When SIJ dysfunction is present in conjunction with other primary pain generators (such as lumbar radiculitis secondary to degenerative disc disease or lumbar facet arthropathy secondary to lumbar facet arthritis, treatment should first address the non-SIJ pain generators, as SI joint dysfunction may resolve once these pain generators have been successfully treated. If there is residual SI pain, it may be appropriate to perform SIJ injections to address the remaining pain
 - Only one type of a block or injection (e.g., sacroiliac, epidural) should be performed in each session so that the effectiveness of its treatment can be assessed prior to attempting another type of spinal block or injection

DOCUMENTATION REQUIREMENTS. Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

SUMMARY OF MEDICAL EVIDENCE

Radiofrequency Ablation (RFA)

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033

Last Approval: 4/10/2024
Next Review Due By: April 2025



The therapeutic efficacy and duration of impact of RFA in the sacroiliac joint (SIJ) have not been reliably demonstrated in well-designed studies. Randomized controlled trial (RCT) evidence is limited, comprises small sample sizes, and assesses primarily short-term results following RFA treatment. The medical literature does not provide sufficient evidence to establish the safety and efficacy of SIJ RFA or the precise innervation of the joint. Studies assessed in published systematic reviews, Cochrane reviews, and technology assessments overlap. There is inadequate data in the peer-reviewed scientific literature to establish the safety and efficacy of various ablative modalities (e.g., laser, chemical, or electrical) when used to treat SIJ and other related types of pain.

RFA as a treatment for SIJ pain has been studied in several pilot studies, retrospective case series, and prospective case series (Bellini and Barbieri 2016; Romero et al. 2015; Ho et al. 2013). Furthermore, two RCTs comparing cooled radiofrequency ablation (CRFA) to conventional radiofrequency (Cheng et al. 2013) and CRFA to a new bipolar radiofrequency approach (Cheng et al. 2016) for the treatment of SI joint pain have been published. However, sample numbers are small in these trials, follow-up varies from 12 weeks to 2 years, patient selection criteria vary, procedure varies, and controls are insufficient.

A health technology assessment evaluated the effectiveness and safety of conventional radiofrequency ablation (RFA) for sacroiliac joint (SIJ) denervation in addressing lower back pain (LBP) among adult populations. The assessment encompassed ten studies, comprising four randomized controlled trials, four retrospective comparative studies, one prospective pretest-posttest study, and one prospective cohort study, with follow-up periods spanning from three months to 6 years. Studies compared conventional RFA with conservative management, sham RFA, SIJ block with corticosteroid injection, cooled RFA, pulsed RF, and SIJ fusion. Based on a low-quality body of evidence, the assessment suggests that conventional RFA may be effective in mitigating LBP in adults. However, there is uncertainty regarding its long-term effectiveness in pain alleviation, as well as its influence on long-term pain medication utilization, disability/functionality, and quality of life (QOL). The low-quality evidence is attributed to several factors, including the inherent limitations within individual studies, significant procedural heterogeneity across investigations, modest sample sizes in most studies, inconsistent findings concerning functional outcomes, and a paucity of studies examining outcomes beyond pain and functionality. The overall body of evidence suggests that conventional RFA for SIJ denervation is presumably safe and may confer benefits in diminishing chronic LBP (Hayes¹ 2023).

Cooled Radiofrequency Ablation

There is insufficient published evidence to support the use of CRFA for the treatment of facet joint or sacroiliac pain. Additional RCTs with longer follow up and larger patient populations are required. The evidence is insufficient to determine the effects of this technology on net health outcomes.

A Cochrane review evaluated the evidence for radiofrequency denervation as a treatment for chronic LBP and concluded that while the results were inconsistent for disc pain, low-quality evidence revealed no differences in pain and function between radiofrequency denervation and placebo in the short-term for SIJ pain (Maas et al. 2015). One trial indicated a minor improvement on pain and function for SIJ discomfort, but there is no high-quality data that radiofrequency denervation relieves back pain.

A randomized multicenter study (Mint Study) evaluating the effectiveness of radiofrequency denervation added to a standardized exercise program for subjects with chronic LBP (n=681) was published by (Juch et al. 2017). Subjects with chronic LBP, a positive past diagnostic block of the facet (n=251), sacroiliac (n=228), or a combination of joints (n=202), and an inability to respond to conservative therapy were included. All subjects got a 3-month conventional exercise regimen and, if necessary, psychological support; the experimental group also received radiofrequency denervation (1 to 3 treatments were allowed). The primary outcome was pain intensity 3 months after treatment, with a 12-month follow-up: 599 subjects (88%) completed the 3-month follow-up and 521 subjects (77%). The authors concluded that when compared to a conventional exercise program alone, radiofrequency denervation combined with a standard exercise program resulted in either no improvement or no clinically significant improvement in LBP.

Sun et al. (2018) conducted a meta-analysis on the efficacy and safety of CRFA for SI joint pain. Seven studies (4 retrospective observational, 2 RCTs, and one prospective observational) with 240 patients (n=240) met the criteria for inclusion: persistent SI joint pain, CRFA as the intervention, and three-month results. The overall pooled results showed decreased pain intensity compared to pre-treatment pain using visual analog scale and numeric rating scale (3.78, 3.81), reduced disability scores using Oswestry Disability Index (ODI), and 72% of individuals had good results utilizing

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033

Last Approval: 4/10/2024
Next Review Due By: April 2025



Global Perceived Effect. The studies found no serious side effects. The authors point out that small sample sizes within studies, observational studies, and discrepancies in diagnostic block cutoff values (50% versus 75%) all contribute to the potential for placebo effect. The authors found that despite study variances, analysis supported the safety and efficacy of CRFA for SIJ pain.

Chou et al. (2021) recommended against radiofrequency denervation for the management of chronic LBP in an evidence-based peer-review on nonsurgical interventional treatment for LBP. The available data are inconclusive and suggest that, when compared to placebo, radiofrequency denervation may reduce pain in the short term; however, there does not appear to be any long-term benefit. Radiofrequency denervation adds little to a treatment regimen that includes a regular exercise program and psychologic support (Juch et al. 2017). Discogenic LBP, radicular pain, and chronic SIJ pain have all shown no efficacy or only modest, mostly short-term benefit in small clinical trials.

A Health Technology Assessment (December 2022) assessed the effectiveness and safety of CRFA and PRF for the treatment of chronic LBP that originates from the SIJ.

- The use of CRFA in adults for chronic LBP caused by SIJ is regarded as potentially beneficial but unproven. This rating reflects an overall low-quality body of evidence indicating that SIJ CRFA is safe and may be effective for 6 to 12 months in reducing the intensity of chronic LBP and improving physical function. This rating also reflects significant uncertainty about the long-term durability, impact on quality of life, and effectiveness of CRFA in comparison to most treatment alternatives.
- The use of PRFA to treat chronic LBP arising from the SIJ in adults is rated as insufficient evidence due to the 'very small and limited body of published evidence' to assess the safety and/or impact on health outcomes or patient management. This HTA based the rating on an overall very low-quality body of evidence that is insufficient to allow any conclusions regarding the efficacy and safety of PRF for treatment of chronic LBP arising from the SIJ.

Sacroiliac Joint Injections

The current peer-reviewed published literature for SIJ injections with corticosteroids and local anesthetic for treatment of chronic LBP consists of RCTs prospective cohort studies and retrospective reviews. There are no randomized trials of intraarticular SIJ steroid injection versus a sham procedure in patients without spondyloarthritis (Chou 2021).

Janapala et al. (2023) conducted a systematic review and meta-analysis to assess the efficacy of therapeutic sacroiliac joint injections. The analysis included 11 randomized controlled trials (RCTs) and 3 observational studies, involving 641 patients. The primary outcomes evaluated were pain relief measured by the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS) and functional status measured by the Oswestry Disability Index (ODI). Outcomes were considered clinically significant if there was a reduction of 3 points on the VAS or NRS, 50% decrease in pain coupled with improved functional status. Positive outcomes were observed in five RCTs and two observational studies. Pain scores decreased by 2.979 points ($p < 0.0001$) at three months across eight studies, and functional scores decreased by 18.057 points ($p < 0.0001$) across four studies. At six months, pain scores decreased by 3.069 points ($p < 0.0001$) based on three studies, and ODI scores decreased by 5.240 points ($p < 0.0001$) across three studies. However, the review is constrained by a lack of eligible studies, discrepancies among available studies, methodological variations, and inconsistent diagnostic criteria. Despite these limitations, the evidence suggests that therapeutic sacroiliac joint injections offer moderate support for managing low back pain originating from the sacroiliac joint.

A randomized controlled trial compared the short-term efficacy of 3 treatments in 51 patients ($n=51$) with chronic SIJ-related leg pain: fluoroscopically guided SIJ injection with lidocaine plus triamcinolone, PT, and manual therapy (Visser et al. 2013). SIJ-related pain was not confirmed by diagnostic injection. The findings indicate that treatment effectiveness rates (as measured by pain relief) between the SIJ injection (50%), manual therapy (72%) or PT groups (20%). Manual therapy was substantially more effective than PT. There were no reported side effects from the treatment. The limitations of this study include a small sample size and lack of power analysis, a single-blind design, a short duration of follow-up, a lack of diagnostic injections to confirm the diagnosis of SIJ pain, possible selection bias during patient recruitment, and a failure to rule out discogenic causes of LBP as opposed to SIJ pathology.

Jee et al. (2014), in a RCT of 120 patients ($n = 120$) with noninflammatory SI arthritis, ultrasound (US)-guided SIJ injections, compared to fluoroscopic (FL)-guided SIJ injections to evaluate the short-term efficacy and safety of US and FL-guided SIJ injections. Patients were not blinded, but an investigator who was blinded assessed their pain, disability, and satisfaction. The FL-guided SIJ approach was more accurate than the US-guided approach (98.2%

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033

Last Approval: 4/10/2024
Next Review Due By: April 2025



versus 87.2%). The function and pain relief of both groups improved without significant differences. The US-guided strategy is just as effective as the FL-guided strategy; however, the SIJ's lower diagnostic accuracy rate may limit its diagnostic utility.

A health technology assessment was conducted to evaluate the efficacy and safety of SIJ corticosteroid injections in the management of SIJ pain and LBP among adult individuals. The quality of evidence pertaining to the effectiveness of such injections was deemed to be low. Among the six studies encompassed within the assessment, two reported a significant improvement in pain outcomes after corticosteroid injections when compared to baseline measurements. Comparative analysis with alternative therapies, such as platelet-rich plasma injections, manual therapy, physical therapy, and standard radiofrequency ablation, demonstrated a comparable efficacy profile. However, due to variances observed in patient selection criteria, treatment protocols, comparators utilized, assessment intervals, and the absence of prolonged follow-up evaluations, the effectiveness of SIJ corticosteroids remains uncertain. Consequently, the health technology assessment inferred weak evidential support for the utilization of SIJ corticosteroid injections in the management of SIJ-related discomfort and LBP among the adult populace (Hayes² 2023).

National and Specialty Organizations

Agency for Healthcare Research and Quality (AHRQ) conducted a comparative effectiveness review on CRFA for the treatment of sacroiliac and facet joint pain (Chou et al. 2021). At 1-month, CRFA for sacroiliac pain was associated with a moderate to large reduction in pain and a small to large improvement in function when compared to sham radiofrequency. At three months, pain and function had improved moderately. There is insufficient evidence beyond 6 months. Furthermore, the trials used a variety of techniques, with insufficient evidence to determine the best method. CRFA for presumed facet joint pain was associated with a small, non-statistically significant reduction in pain and no difference in function at 6 months compared to conventional RFA. At the 1- and 3-month follow-ups, there were no differences. There is insufficient evidence beyond 6 months. All studies had small sample sizes and short follow-up periods. Longer-term studies with larger sample sizes are required to confirm these findings.

The **American Society of Anesthesiologists (ASA) / American Society of Regional Anesthesia and Pain Medicine (ASRA)** published *Practice Guidelines for Chronic Pain Management* (2010) with the following:

- The medical literature is insufficient to evaluate the efficacy of RFA for SIJ pain, although the guideline states that water-cooled RFA may be used for chronic SIJ pain. The task force recommended that neuroablative procedures be used as part of a comprehensive pain management regimen, and that they be used only as a last resort when other treatments have failed. There has been no update to the report located.
- SIJ injections may be considered for symptomatic relief of SIJ pain.

American Society of Interventional Pain Physicians (ASIPP)

'An Update of Comprehensive Evidence-Based Guidelines for Interventional Techniques in Chronic Spinal Pain (Manchikanti et al. 2013) indicates:

- There was fair-quality evidence of the efficacy of CRFA for SIJ pain.
- The evidence of effectiveness of PRF of the SIJ was considered limited.
- The evidence for intraarticular injections as an intervention for SIJ indications is limited.

Institute for Clinical Systems Improvement (ICSI)

- ICSI guideline 'Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management Care for Adults' issued in 2017 indicate that conflicting evidence exists regarding the efficacy of SIJ injections for management of LBP.
- The guideline also notes that mixed evidence exists regarding the efficacy of RF neurotomy (ICSI 2017).

North American Spine Society (NASS)

The 'Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis and Treatment of Low Back Pain,' published in 2020, assigned a grade of C to the following recommendations, indicating poor quality evidence (Level IV or V studies) for or against recommending intervention:

- Intraarticular SIJ injections with steroid may be considered in patients with suspected SIJ pain, and
- CRFA of the sacral lateral branch nerves and dorsal ramus of L5 may be considered in patients with sacroiliac joint pain diagnosed with dual diagnostic blocks (NASS 2020).

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033

Last Approval: 4/10/2024
Next Review Due By: April 2025



CODING & BILLING INFORMATION

CPT (Current Procedural Terminology) Codes

Code	Description
27096	Injection procedure for sacroiliac joint, anesthetic/steroid, with image guidance (fluoroscopy or CT) including arthrography when performed
64451	Injection(s), anesthetic agent(s) and/or steroid; nerves innervating the sacroiliac joint, with image guidance (i.e., fluoroscopy or computed tomography)
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (e.g., fluoroscopy or computed tomography)

HCPCS (Healthcare Common Procedure Coding System) Code

Code	Description
G0260	Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

APPROVAL HISTORY

4/10/2024	Policy reviewed, no changes to coverage criteria. Updated Summary of Medical Evidence and References.
4/13/2023	Policy reviewed and updated. No changes to intent of policy or coverage criteria. Added updated literature to the 'Summary of Evidence' section. Updated references.
4/13/2022	Policy reviewed and updated. No changes in coverage criteria (revised verbiage and language for clarity but no changes in intent). Updated Overview, Summary of Evidence, and References section.
4/5/2021	Policy reviewed, no changes to the criteria. Added CPT 64451 & 64625. Policy reviewed by practicing, board-certified physician in Pain Management, Physical Medicine and Rehabilitation.
4/23/2020	Policy reviewed, changed PT requirement to a minimum of 4 weeks to be consistent with other guidelines and Molina pain management MCRs. Updated coding table: Added HCPCS code G0259 and removed CPT codes 64635 & 64636. Policy reviewed by practicing, board-certified physician in Pain Management, Physical Medicine and Rehabilitation.
6/19/2019	Policy reviewed, no changes to criteria.
3/8/2018	Policy reviewed, no changes to criteria.
7/1/2017	Reduced PT requirement from 20 sessions to 10-12 sessions over 8 weeks, changed improvement scales from significant functional improvement of 80% improvement in 6 weeks to significant functional pain relief of 50% measured by a decrease in pain medication and increase in functional ability for a minimum of 2 months. Coding tables updated. Changes are based on 2017 ODG Guidelines per AMR review. Policy reviewed by practicing, board-certified physician in Pain Management, Physical Medicine and Rehabilitation
6/15/2016	Policy reviewed, no changes to criteria.
12/16/2015	Policy reviewed, no changes to criteria.
6/25/2014	Policy reviewed, no changes to criteria.
12/11/2013	Policy reviewed, no changes to criteria.
8/23/2012	Policy reviewed, no changes to criteria.
12/3/2009	Policy reviewed, no changes to criteria.
7/5/2007	New policy.

REFERENCES

- American Society of Anesthesiologists (ASA) Task Force on Pain Management and American Society of Regional Anesthesia (ASRA). Practice guidelines for chronic pain management: An updated report by the ASA Task Force on Chronic Pain Management and the ASRA and Pain Medicine. *Anesthesiology*. 2010;112(4):810-833. <https://doi.org/10.1097/ALN.0b013e3181c43103>.
- Bellini M, Barbieri M. Single strip lesions radiofrequency denervation for treatment of sacroiliac joint pain: Two years' results. *Anaesthesiol Intensive Ther*. 2016;48(1):19-22. doi: 10.5603/AIT.2016.0004.

Molina Clinical Policy

Sacroiliac Injections and Radiofrequency Ablation (RFA) for Sacroiliac Joint Pain: Policy No. 033



Last Approval: 4/10/2024

Next Review Due By: April 2025

3. Cheng J, Pope JE, Dalton JE, Cheng O, Bensitel A. Comparative outcomes of cooled versus traditional radiofrequency ablation of the lateral branches for sacroiliac joint pain. *Clin J Pain*. 2013 Feb;29(2):132–7. doi: 10.1097/AJP.0b013e3182490a17.
4. Cheng J, Chen SL, Zimmerman N, et al. A new radiofrequency ablation procedure to treat sacroiliac joint pain. *Pain Physician*. 2016 Nov-Dec;19(8):603-615. PMID: 27906939.
5. Chou R, Fu R, Dana T, et al. *Interventional Treatments for Acute and Chronic Pain: Systematic Review [Internet]*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. (Comparative Effectiveness Review, No. 247.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK573963/> doi: 10.23970/AHRQEPCCER247.
6. Chou R. Subacute and chronic low back pain: Nonsurgical interventional treatment. Updated June 10, 2021. Accessed March 5, 2024. <http://www.uptodate.com>.
7. ¹ Hayes. Health technology assessment: Conventional radiofrequency ablation for sacroiliac joint denervation for chronic low back pain. Published December 6, 2022. Updated December 28, 2023. Accessed March 6, 2024. <http://www.hayesinc.com>.
8. ² Hayes. Health technology assessment: Sacroiliac joint injection with corticosteroids for treatment of sacroiliac joint and low back pain. Published June 13, 2023. Accessed March 5, 2024. <http://www.hayesinc.com>.
9. Ho KY, Hadi MA, Pasutharnchat K, Tan KH. Cooled radiofrequency denervation for treatment of sacroiliac joint pain: Two-year results from 20 cases. *J Pain Res*. 2013 Jul 4;6:505-11. doi: 10.2147/JPR.S46827.
10. Institute for Clinical Systems Improvement. Hooten M, Thorson D, Bianco J, et al. Pain: assessment, non-opioid treatment approaches and opioid management. Updated August 2017. <https://www.icsi.org/guideline/pain/>.
11. Janapala RN, Knezevic E, Knezevic NN, et al. Systematic Review and Meta-Analysis of Effectiveness of Therapeutic Sacroiliac Joint Injections. *Pain Physician*. 2023 Sep;26(5):E413-E435. PMID: 37774179.
12. Jee H, Lee JH, Park KD, Ahn J, Park Y. Ultrasound-guided versus fluoroscopy-guided sacroiliac joint intra-articular injections in the noninflammatory sacroiliac joint dysfunction: A prospective, randomized, single-blinded study. *Arch Phys Med Rehabil*. 2014;95(2):330-337. doi: 10.1016/j.apmr.2013.09.021.
13. Juch JNS, Maas ET, Ostelo RWJG, et al. Effect of radiofrequency denervation on pain intensity among patients with chronic low back pain: The Mint Randomized Clinical Trials. *JAMA*. 2017 Jul 4;318(1):68-81. doi:10.1001/jama.2017.7918.
14. Lee DW, Pritzlaff S, Jung MJ, et al. Latest Evidence-based Application for Radiofrequency Neurotomy (LEARN): Best practice guidelines from the American Society of Pain and Neuroscience (ASPN). *J Pain Res*. 2021;14:2807-2831. doi:10.2147/jpr.S325665.
15. Maas ET, Ostelo RW, Niemisto L, Jousimaa J, Hurri H, Malmivaara A, van Tulder MW. Radiofrequency denervation for chronic low back pain. *Cochrane Database Syst Rev*. 2015 Oct 23;2015(10):CD008572. doi: 10.1002/14651858.CD008572.pub2. PMID: 26495910; PMCID: PMC8782593.
16. Manchikanti L, Abdi S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. *Pain Physician*. 2013 Apr;16(2 Suppl):S49-283. PMID: 23615883.
17. NASS Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care: Diagnosis & Treatment of Low Back Pain. 2020. Accessed March 5, 2024. <https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf>.
18. Romero FR, Vital RB, Zanini MA, Ducati LG, Gabarra RC. Long-term follow-up in sacroiliac joint pain patients treated with radiofrequency ablative therapy. *Arq Neuropsiquiatr*. 2015 Jun;73(6):476-9. doi: 10.1590/0004-282X20150049.
19. Sun HH, Zhuang SY, Hong X, et al. The efficacy and safety of using cooled radiofrequency in treating chronic sacroiliac joint pain: A PRISMA-compliant meta-analysis. *Medicine* 97(6);p e9809, February 2018. DOI: 10.1097/MD.0000000000009809.
20. Thawrani DP, Agabegi SS, Asghar F. Diagnosing sacroiliac joint pain. *J Am Acad Orthop Surg*. 2019;27(3):85-93. doi:10.5435/jaaos-d-17-00132. doi: 10.5435/JAAOS-D-17-00132.
21. Visser LH, Woudenberg NP, de Bont J, et al. Treatment of the sacroiliac joint in patients with leg pain: A randomized-controlled trial. *Eur Spine J*. 2013;22(10):2310-2317. doi: 10.1007/s00586-013-2833-2. Epub 2013 May 30.
22. Wieczorek A, Campau E, Pionk E, Gabriel-Champine ME, Ríos-Bedoya CF. A Closer Look into the Association between the Sacroiliac Joint and Low Back Pain. *Spartan Med Res J*. 2021 Apr 13;6(1):21971. doi: 10.51894/001c.21971. PMID: 33870003; PMCID: PMC8043903.
23. Wray JK, Dixon B, Przkora R. Radiofrequency ablation. Updated September 7, 2022. In: *StatPearls [Internet]*. Treasure Island, FL: StatPearls Publishing; 2022. Accessed February 2023. <https://www.ncbi.nlm.nih.gov/books/NBK482387/>.